| Long-term efficacy of vedolizumab for ulcerative colitis EV Loftus Jr, JF Colombel, BG Feagan, S Vermeire, WJ Sandborn, ... Journal of Crohn's and Colitis 11 (4), 400-411, 2017 | 245 | 2017 |
| Long-term efficacy of vedolizumab for Crohn’s disease S Vermeire, EV Loftus Jr, JF Colombel, BG Feagan, WJ Sandborn, ... Journal of Crohn's and Colitis 11 (4), 412-424, 2017 | 243 | 2017 |
| Efficacy of vedolizumab induction and maintenance therapy in patients with ulcerative colitis, regardless of prior exposure to tumor necrosis factor antagonists BG Feagan, DT Rubin, S Danese, S Vermeire, B Abhyankar, S Sankoh, ... Clinical Gastroenterology and Hepatology 15 (2), 229-239. e5, 2017 | 239 | 2017 |
| Exposure–efficacy relationships for vedolizumab induction therapy in patients with ulcerative colitis or Crohn’s disease M Rosario, JL French, NL Dirks, S Sankoh, A Parikh, H Yang, S Danese, ... Journal of Crohn's and Colitis 11 (8), 921-929, 2017 | 161 | 2017 |
| Systematic review with network meta-analysis: comparative efficacy of biologics in the treatment of moderately to severely active ulcerative colitis AD Vickers, C Ainsworth, R Mody, A Bergman, CS Ling, J Medjedovic, ... PLoS One 11 (10), e0165435, 2016 | 127 | 2016 |
| Assessment of survival in a 2-year comparative study of lanthanum carbonate versus standard therapy R Wilson, P Zhang, M Smyth, R Pratt Current medical research and opinion 25 (12), 3021-3028, 2009 | 91 | 2009 |
| The effect of sevelamer carbonate and lanthanum carbonate on the pharmacokinetics of oral calcitriol D Pierce, S Hossack, L Poole, A Robinson, H Van Heusen, P Martin, ... Nephrology Dialysis Transplantation 26 (5), 1615-1621, 2011 | 79 | 2011 |
| Burden of disease associated with X-linked hypophosphataemia in adults: a systematic literature review L Seefried, M Smyth, R Keen, P Harvengt Osteoporosis International 32, 7-22, 2021 | 54 | 2021 |
| Comparison of dietary phosphate absorption after single doses of lanthanum carbonate and sevelamer carbonate in healthy volunteers: a balance study P Martin, P Wang, A Robinson, L Poole, J Dragone, M Smyth, R Pratt American journal of kidney diseases 57 (5), 700-706, 2011 | 54 | 2011 |
| The international X-linked hypophosphataemia (XLH) registry (NCT03193476): rationale for and description of an international, observational study R Padidela, O Nilsson, O Makitie, S Beck-Nielsen, G Ariceta, D Schnabel, ... Orphanet journal of rare diseases 15, 1-11, 2020 | 38 | 2020 |
| Cost-effectiveness of vedolizumab compared with infliximab, adalimumab, and golimumab in patients with ulcerative colitis in the United Kingdom MR Wilson, A Bergman, H Chevrou-Severac, R Selby, M Smyth, ... The European Journal of Health Economics 19, 229-240, 2018 | 36 | 2018 |
| Cost-effectiveness of lanthanum carbonate versus sevelamer hydrochloride for the treatment of hyperphosphatemia in patients with end-stage renal disease: a US payer perspective H Park, KL Rascati, MS Keith, P Hodgkins, M Smyth, D Goldsmith, ... Value in Health 14 (8), 1002-1009, 2011 | 29 | 2011 |
| Indicators of suboptimal tumor necrosis factor antagonist therapy in inflammatory bowel disease JO Lindsay, A Armuzzi, JP Gisbert, B Bokemeyer, L Peyrin-Biroulet, ... Digestive and Liver Disease 49 (10), 1086-1091, 2017 | 28 | 2017 |
| Sa1271 efficacy of vedolizumab with concomitant corticosteroid or immunomodulator use in patients with ulcerative colitis from GEMINI 1 JF Colombel, EV Loftus, CA Siegel, J Lewis, MD Smyth, S Sankoh, ... Gastroenterology 148 (4), S-277-S-278, 2015 | 24 | 2015 |
| Results of a pilot program to improve phosphorus outcomes in hemodialysis patients TJ Mayne, D Benner, K Ricketts, M Burgess, S Wilson, L Poole, M Smyth, ... Journal of Renal Nutrition 22 (5), 472-479, 2012 | 20 | 2012 |
| P497 Efficacy of continued vedolizumab therapy in patients with Crohn's disease who did not respond to vedolizumab induction therapy at week 6 WJ Sandborn, B Feagan, W Reinisch, M Smyth, J Xu, A Parikh, I Fox Journal of Crohn's and Colitis, S274-S275, 2014 | 17 | 2014 |
| Lanthanum carbonate reduces urine phosphorus excretion: evidence of high-capacity phosphate binding M Pennick, L Poole, K Dennis, M Smyth Renal Failure 34 (3), 263-270, 2012 | 17 | 2012 |
| Sa1261 Vedolizumab for the Treatment of Fistulizing Crohn's Disease: An Exploratory Analysis of Data From GEMINI 2 BG Feagan, DA Schwartz, S Danese, DT Rubin, B Abhyankar, MD Smyth, ... Gastroenterology 148 (4), S-274, 2015 | 15 | 2015 |
| Long-Term Efficacy of Vedolizumab Therapy for Patients With Ulcerative Colitis: Presidential Poster: 1616 B Feagan, A Kaser, M Smyth, R Panaccione, S Sankoh, B Abhyankar Official journal of the American College of Gastroenterology| ACG 109, S477-S478, 2014 | 13 | 2014 |
| P501 Effects of continued vedolizumab therapy for ulcerative colitis in week 6 induction therapy nonresponders B Feagan, WJ Sandborn, M Smyth, S Sankoh, A Parikh, I Fox Journal of Crohn's and Colitis, S276-S277, 2014 | 12 | 2014 |
Brihad AbhyankarTheravance Biopharma Ireland LtdΗ διεύθυνση ηλεκτρονικού ταχυδρομείου έχει επαληθευτεί στον τομέα theravance.com
